Charles A. Deignan Sells 14,030 Shares of Clearside Biomedical, Inc. (NASDAQ:CLSD) Stock

Clearside Biomedical, Inc. (NASDAQ:CLSD – Get Rating) CFO Charles A. Deignan sold 14,030 shares of the business’s stock in a transaction dated Thursday, January 19th. The stock was sold at an average price of $1.50, for a total transaction of $21,045.00. Following the sale, the chief financial officer now directly owns 363,472 shares in the company, valued at $545,208. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Clearside Biomedical Stock Performance

Shares of CLSD opened at $1.50 on Monday. Clearside Biomedical, Inc. has a 52 week low of $0.98 and a 52 week high of $2.85. The firm has a market cap of $90.29 million, a P/E ratio of -18.75 and a beta of 1.83. The firm’s 50-day simple moving average is $1.27 and its 200 day simple moving average is $1.35.

Clearside Biomedical (NASDAQ:CLSD – Get Rating) last announced its quarterly earnings results on Wednesday, November 9th. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.17). Clearside Biomedical had a negative net margin of 17.15% and a negative return on equity of 16.13%. The company had revenue of $0.27 million during the quarter, compared to analyst estimates of $16.50 million. As a group, equities analysts forecast that Clearside Biomedical, Inc. will post -0.52 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of CLSD. Newman Dignan & Sheerar Inc. acquired a new position in shares of Clearside Biomedical during the 3rd quarter worth approximately $31,000. Mackenzie Financial Corp grew its position in shares of Clearside Biomedical by 184.5% during the 2nd quarter. Mackenzie Financial Corp now owns 33,448 shares of the company’s stock worth $49,000 after purchasing an additional 21,691 shares in the last quarter. Renaissance Technologies LLC grew its position in shares of Clearside Biomedical by 101.5% during the 1st quarter. Renaissance Technologies LLC now owns 864,951 shares of the company’s stock worth $1,981,000 after purchasing an additional 435,734 shares in the last quarter. State Street Corp grew its position in shares of Clearside Biomedical by 5.2% during the 1st quarter. State Street Corp now owns 193,363 shares of the company’s stock worth $443,000 after purchasing an additional 9,475 shares in the last quarter. Finally, Bank of America Corp DE grew its position in shares of Clearside Biomedical by 2,760.2% during the 1st quarter. Bank of America Corp DE now owns 120,500 shares of the company’s stock worth $276,000 after purchasing an additional 116,287 shares in the last quarter. Institutional investors and hedge funds own 20.07% of the company’s stock.

Analysts Set New Price Targets

CLSD has been the topic of several analyst reports. HC Wainwright boosted their price target on shares of Clearside Biomedical from $5.00 to $6.00 and gave the stock a “buy” rating in a research report on Thursday, November 10th. StockNews.com initiated coverage on shares of Clearside Biomedical in a research report on Friday, November 4th. They set a “hold” rating on the stock. Needham & Company LLC raised shares of Clearside Biomedical from a “hold” rating to a “buy” rating and set a $5.00 price target on the stock in a research report on Thursday, November 10th. Finally, Stifel Nicolaus raised shares of Clearside Biomedical from a “hold” rating to a “buy” rating and set a $8.00 target price on the stock in a report on Wednesday, November 9th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $7.60.

Clearside Biomedical Company Profile

(Get Rating)

Clearside Biomedical, Inc is a biopharmaceutical company, which delivers therapies to the back of the eye through the suprachoroidal space. Its pipeline include CLS-AX, Integrin Inhibitor, and gene therapy. The company was founded by Samir Kumar Patel, Vladimir Zarnitsyn, Mark Prausnitz, Daniel H. White, and Henry F.